It is worth mentioning that sodium glucose cotransporter 2 (SGLT-2) inhibitors, a recent class of antidiabetic medications, have been shown to effectively attenuate inflammation, oxidative stress and fibro-genesis and clinical trials involving the use of these drugs in NAFLD are ongoing [43, 44]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.